Photocure ASA (PHCUF) has released an update.
Photocure ASA reported Hexvix/Cysview revenues of NOK 122.4 million in Q2 2024, marking a 6% increase from Q2 2023, and an EBITDA growth to NOK 27.8 million. The company confirms its 2024 financial outlook, anticipating a 6% to 9% revenue growth and positive EBITDA, excluding business development costs. Additionally, Photocure updates its projections for new and upgraded Saphira installations in the U.S., now expecting 55 to 70 units by year-end.
For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.
